<DOC>
	<DOCNO>NCT02045017</DOCNO>
	<brief_summary>The primary purpose study determine safety efficacy generate PK biomarker data combination Pomalidomide low-dose Dexamethasone patient relapse refractory multiple myeloma , moderate severe renal impairment .</brief_summary>
	<brief_title>Efficacy Safety Pomalidomide Dexamethasone RRMM Patients With Renal Insufficiency</brief_title>
	<detailed_description>The study consist Screening phase within 28 day prior cycle 1 day 1 . Subjects enrol enter Treatment phase , patient treat progression , study discontinuation due reason . Subjects enter long term Follow-up phase study data collect every 3 month 5 year Secondary primary malignancy , survival , subsequent anti myeloma treatment date progression . Subjects recruit one 3 cohort depend severity renal impairment .</detailed_description>
	<mesh_term>Multiple Myeloma</mesh_term>
	<mesh_term>Neoplasms , Plasma Cell</mesh_term>
	<mesh_term>Renal Insufficiency</mesh_term>
	<mesh_term>Dexamethasone acetate</mesh_term>
	<mesh_term>Dexamethasone</mesh_term>
	<mesh_term>Dexamethasone 21-phosphate</mesh_term>
	<mesh_term>Pomalidomide</mesh_term>
	<mesh_term>Thalidomide</mesh_term>
	<mesh_term>BB 1101</mesh_term>
	<criteria>Subjects must satisfy follow criterion enrol study . 1 . Subjects must document diagnosis multiple myeloma measurable disease ( serum Mprotein ≥ 0.5 g/dL urine Mprotein ≥ 200 mg/24 hour ) . 5 . Subjects must least 1 prior antimyeloma regimen include lenalidomide document progression per International Myeloma Working Group uniform response criterion ( Durie , 2006 ) last antimyeloma regimen . Induction therapy follow Autologous Stem Cell Transplant consolidation/ maintenance consider one regimen . 6 . Subjects must impair renal function estimate Glomerular Filtrate Rate &lt; 45 mL/min/1.73 m2 accord modification diet renal disease equation . 1 . Impaired renal function must due multiple myeloma need confirm kidney biopsy . 2 . Subjects may acute myeloma relate renal failure chronic myeloma relate renal failure ; may also treat dialysis , include dialysis high cut membrane . The presence follow exclude subject enrollment 1 . Any significant medical condition , laboratory abnormality , psychiatric illness would prevent subject participate study . 2 . Any condition include presence laboratory abnormality , place subject unacceptable risk he/she participate study . 3 . Renal insufficiency due reason multiple myeloma due hypocalcaemia . 4 . Prior history malignancy , MM , unless subject free disease ≥ 5 year ; exception include follow : 1 . Basal squamous cell carcinoma skin 2 . Carcinoma situ cervix breast 3 . Incidental histological finding prostate cancer ( Tumour lymphNode Metastasis stage T1a T1b ) 6 . Previous therapy pomalidomide . 7 . Hypersensitivity thalidomide , lenalidomide , dexamethasone ( include ≥ Grade 3 rash prior thalidomide lenalidomide therapy ) . 10 . Subjects plan eligible stem cell transplant .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>September 2016</verification_date>
	<keyword>Multiple Myeloma</keyword>
	<keyword>Relapsed Multiple Myeloma</keyword>
	<keyword>Refactory Multiple Myeloma</keyword>
	<keyword>Renal Insufficiency</keyword>
	<keyword>Pomalidomide</keyword>
	<keyword>Dexamethasone</keyword>
</DOC>